CeriBell, Inc.

NASDAQ:CBLL

Medical - Devices

Healthcare
$25.63 +1.42%

+$0.25 today

Market cap
$995.34M
Beta
0.84
P/E (TTM)
-10.9
EPS (TTM)
-$1.60
52W Low $10.85High $24.33

Volume 0.41M

Average 0.29M

CBLL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CeriBell, Inc.NASDAQ: CBLL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $6.16M rose 45.1% year over year, ahead of the +43.4% change in trailing-twelve-month research & development. Sequentially, it rose 21.7% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.

Context

  • Research & development amounted to 21.5% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +45.1% holds above the trailing-twelve-month pace of +43.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.16M+21.7% QoQ
Last fiscal yearDec 2025
$19.14M+41.2% YoY
LTMMar 2026
$21.06M+43.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.1%——
1 year+41.2%——
3-year CAGR+38.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
19.14M USD
Year-over-year change
+41.2%
3-year CAGR
+38.3%

Research & Development vs competitors

How CBLL compares with its peers on the latest reported figures

  • CBLL's LTM Mar 2026 research & development of $21.06M is the 3rd highest of the 7 companies compared; the peer median is $10.93M.
  • Its year-over-year change of +43.4% is the highest of 7, against a peer median of +9.8%.
  • Research & development amounts to 22.2% of revenue for CBLL, versus a peer median of 15.8%.
CBLL Competitors Peer median
Research & Development for CBLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LIVNLivaNova PLCLTM Sep 2026$202.57M +14.5%+6.0%13.4%
NPCENeuroPace, Inc.LTM Mar 2026$27.64M +9.2%+8.3%27.8%
CBLLCeriBell, Inc.LTM Mar 2026$21.06M +43.4%+38.3%22.2%
CVRXCVRx, Inc.LTM Mar 2026$11.7M +10.5%+3.8%19.8%
BWAYBrainsWay Ltd.LTM Mar 2026$10.15M +28.6%+7.7%18.1%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M -47.4%-11.0%4.2%
ECORelectroCore, Inc.LTM Mar 2026$2.83M +8.8%-20.9%8.1%
Peer median (excluding CBLL) $10.93M+9.8%+4.9%15.8%

Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.92M45.23M65.44M89.06M
Cost of Revenue4.43M7.06M8.69M10.79M
Gross Profit21.49M38.16M56.75M78.27M
Gross Margin82.9%84.4%86.7%87.9%
Research & Development7.24M9M13.56M19.14M
Selling, General & Admin50.27M59.21M82.9M117.53M
Operating Expenses57.51M68.2M96.46M136.68M
Depreciation & Amortization497K847K1.14M1.34M
EBITDA(35.06M)(26.51M)(37.32M)(50.18M)
EBITDA Margin-135.3%-58.6%-57.0%-56.3%
Operating Income(36.02M)(30.04M)(39.71M)(58.4M)
Operating Margin-139.0%-66.4%-60.7%-65.6%
Interest Income0000
Interest Expense1.6M2.1M1.99M1.89M
Other Income / Expenses(1.14M)588K(746K)4.99M
Income Before Tax(37.16M)(29.45M)(40.46M)(53.41M)
Pre-Tax Margin-143.4%-65.1%-61.8%-60.0%
Income Tax Expense2K11K00
Net Income(37.16M)(29.46M)(40.46M)(53.41M)
Net Margin-143.4%-65.1%-61.8%-60.0%
EPS (Basic)(1.59)(1.26)(3.39)(1.46)
EPS (Diluted)(1.59)(1.26)(3.39)(1.46)
Weighted Avg Shares23.32M23.32M11.95M36.54M
Weighted Avg Shares (Diluted)23.32M23.32M11.95M36.54M

CeriBell, Inc.

NASDAQ:CBLL

Intrinsic Alpha fair value

Locked

Current Price

$25.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.